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S100A11, a member of the S100 family of proteins, is actively secreted from pancreatic ductal adenocarci-
noma (PDAC) cells. However, the role of the extracellular S100A11 in PDAC progression remains unclear. 
In the present study, we investigated the extracellular role of S100A11 in crosstalking between PDAC cells 
and surrounding fibroblasts in PDAC progression. An abundant S100A11 secreted from pancreatic can-
cer cells stimulated neighboring fibroblasts through receptor for advanced glycation end products (RAGE) 
upon S100A11 binding and was followed by not only an enhanced cancer cell motility in vitro but also an 
increased number of the PDAC-derived circulating tumor cells (CTCs) in vivo. Mechanistic investigation of 
RAGE downstream in fibroblasts revealed a novel contribution of a mitogen-activated protein kinase kinase 
kinase (MAPKKK), tumor progression locus 2 (TPL2), which is required for positive regulation of PDAC 
cell motility through induction of cyclooxygenase 2 (COX2) and its catalyzed production of prostaglandin 
E2 (PGE2), a strong chemoattractive fatty acid. The extracellularly released PGE2 from fibroblasts was 
required for the rise in cellular migration as well as infiltration of their adjacent PDAC cells in a cocul-
ture setting. Taken together, our data reveal a novel role of the secretory S100A11 in PDAC disseminative 
progression through activation of surrounding fibroblasts triggered by the S100A11–RAGE–TPL2–COX2 
pathway. The findings of this study will contribute to the establishment of a novel therapeutic antidote to 
PDACs that are difficult to treat by regulating cancer-associated fibroblasts (CAFs) through targeting the 
identified pathway.
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC), the most 
commonly observed type of pancreatic cancer, shows a 
highly aggressive phenotype even at an early stage, lead-
ing to poor survival1,2. One of the mechanisms respon-
sible for its aggressiveness is derived from the renowned 
PDAC feature (i.e., frequent appearance of abundant 
stroma surrounding PDAC)3,4. The tumor stroma is com-
posed of multiple noncancerous cell populations and 
extracellular matrix3,5–8 with about 90% being occupied 
by fibroblasts3,9. Many scientists have therefore focused 
on the specific role of cancer-associated fibroblasts 
(CAFs) in the aggressive progression of PDAC. It has 
been reported that CAFs mediate metastasis8,9, drug resis-
tance1, and immunosuppression10. Therefore CAFs may 
represent a critical target for anti-PDAC therapy. However, 
how CAFs are associated with PDAC aggressiveness at 
molecular levels has still not been fully elucidated.
Bearing in mind that as described above, we paid more 
attention on S100A11, which we have studied so far4,11–17. 
S100A11 is an EF-hand-type calcium-binding protein 
belonging to the S100 family of proteins12. It has become 
evident that S100A11 is overexpressed in PDAC, and 
its high level of expression is linked to poor survival18. 
We recently demonstrated that S100A11 is secreted from 
various kinds of cancer cells including PDAC cell lines 
at significant levels11. It has been shown that extracellular 
S100A11 provides cancer cells with increased ability for 
survival or mobility through receptor for advanced glyca-
tion end products (RAGE) in an autocrine manner12,16,19. 
We therefore considered the possibility that cancer- 
secreted S100A11 can also stimulate fibroblasts surround-
ing PDAC cells since RAGE is positively expressed in 
fibroblasts. The role(s) of extracellular S100A11 in fibro-
blasts and the possible relationship between S100A11-
stimulated fibroblasts and cancer cells in PDAC 
progression have not been studied in detail.
Accordingly, in this study, we aimed to reveal the role 
of fibroblasts in PDAC with focus on the extracellular 
role of cancer-secreted S100A11.
MATERIALS AND METHODS
Cells
HEK293T cells (embryonic kidney cells stably 
expressing the SV40 large T antigen) and PK-8 cells 
(pancreatic carcinoma cells) were obtained from RIKEN 
BioResource Center (Tsukuba, Japan). Another human 
pancreatic cancer cell line, PANC-1, was obtained from 
ATCC (Manassas, VA, USA). Normal human OUMS-24 
fibroblasts were established by Dr. Masayoshi Namba20. 
Wild-type (WT) and RAGE−/− mouse embryonic fibro-
blasts (MEFs) were provided by Professor Yasuhiko 
Yamamoto (Kanazawa University, Kanazawa, Japan). 
To stabilize the cell phenotype and avoid cellular senes-
cence, the prepared primary mouse fibroblasts (WT and 
RAGE−/−) were all immortalized in an autonomous man-
ner through repeated passaging in cell culture21. These 
human and mouse cells were all cultivated in D/F medium 
(Thermo Fisher Scientific, Waltham, MA, USA) supple-
mented with 10% FBS.
Reagents
To selectively inhibit intrinsic kinase activities of TPL2 
and ASK1, we used a TPL2 inhibitor (CAS 871307-18-5; 
Merck Millipore, Kenilworth, NJ, USA) and an ASK1 
inhibitor [Selonsertib (GS-4997); Selleck, Osaka, Japan], 
respectively. Enzymatic activity of cyclooxygenase 2 
(COX2) was suppressed by using a nonselective COX 
inhibitor, aspirin (Cayman Chemical, Ann Arbor, MI, 
USA), or two selective inhibitors of COX2, meloxicam 
(Cayman Chemical), and etodolac (Cayman Chemical). 
PGE2 was purchased from Cayman Chemical.
Human serum specimens from healthy donors [sample 
IDs: R297562 (age, 64 years; gender, female), R297571 
(age, 35 years; gender, male), and R297604 (age, 56 
years; gender, female)] and PDAC patients [sample IDs: 
121229S (age, 39 years; gender, male; grade, G2; stage, 
IIA), 121230S (age, 47 years; gender, male; grade, G2; 
stage, IIA), and 121260S (age, 58 years; gender, male; 
grade, N/A; stage, IIB)] were purchased from Tennessee 
Blood Services (Memphis, TN, USA) and ProteoGenex 
(Inglewood, CA, USA), respectively. To measure concen-
trations of human S100A11 and PGEs in the serum speci-
mens and cell culture media, ELISA kits for S100A11 
(CircuLex S100A11 ELISA kit; CycLex, Nagano, Japan) 
and PGE2 (PGE2 high-sensitivity ELISA kit; Enzo Life 
Sciences, Farmingdale, NY, USA) were used. For in 
vivo mouse experiments, purified mouse IgG (Southern 
Biotech, Birmingham, AL, USA) was used as a control to 
the exRAGE-Fc decoy protein22.
Recombinant Proteins
Highly purified human recombinant S100A11, 
S100A4, and S100A8/A9 proteins were prepared as 
reported previously16,23. The exRAGE-Fc decoy protein 
was prepared from its corresponding conditioned media 
from cultures of FreeStyleTM CHO-S cell (Chinese ham-
ster ovary cell line; Thermo Fisher Scientific)-derived 
stable clone22.
Expression Plasmids
To induce efficient expression of the transgenes in a 
temporal manner, we inserted cDNAs of interest into the 
pIDT-SMART (C-TSC) vector24. The prepared cDNAs 
were as follows: human cDNAs encoding RAGE and 
MAPK cascade upstream kinases (NAK, NIK, TAK1, 
DLK, TPL2, ASK1, SPRK, MLK1, MEKK3, LZK, 
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MLK4, and MKK5) and a kinase dead type of TPL2 
(TPL2-KD; 167K replaced by M). RAGE was designed 
for expression as a C-terminal 3xHA-6His-tagged form. 
MAPK cascade upstream kinases and TPL2-KD were 
designed for expression as C-terminal Myc-6His-tagged 
forms. Cells were transiently transfected with the plas-
mid vectors using FuGENE-HD (Promega, Madison, WI, 
USA).
To obtain PK-8 clones that exhibit a significantly 
high expression level of a foreign gene, GFP alone, or 
GFP + S100A11, in a stable manner, individual GFP 
and S100A11 cDNAs were inserted into the pSAKA-4B 
vector22,25. Using the resulting expression constructs, 
pSAKA-4B-GFP and pSAKA-4B-S100A11, GFP- and 
GFP + S100A11-overexpressed clones were established 
from PK-8 parental cells through a convenient electropo-
ration gene delivery method and following selection with 
puromycin at 20 µg/ml.
Cellular Migration and Invasion Assays  
in a Boyden Chamber
Evaluations of in vitro cellular migration and invasion 
were followed by a convenient Boyden chamber method 
set with Matrigel-noncoating (for migration) or -coating 
Transwell membrane (for invasion). To study the contri-
bution of fibroblasts to cancer cell migration, we seeded 
OUMS-24 normal human fibroblasts (5 × 104 cells/well) 
on the bottom chamber and filled the chamber with 0.5% 
FBS low-serum medium. Before seeding PDAC cells on 
the top chamber, OUMS-24 cells on the bottom chamber 
were treated or not treated with recombinant S100A11 
(100 ng/ml) in the presence or absence of exRAGE-Fc 
(1 µg/ml). After setting PK-8 or PANC-1 cells (5 × 104 
cells/insert) on the upper chamber, an additional 24-h 
incubation was done to assess fibroblast tropic migration 
of PDAC cells.
Another migration assay was also performed by a 
method similar to that described above. In this setting, PK-8 
cell sublines (PK-8 GFP or PK-8 GFP/A11, 5 × 104 cells/
well) and mouse fibroblasts (WT or RAGE−/−, 5 × 104 cells/
well) were simultaneously seeded in various combinations 
between PK-8 cell sublines and mouse fibroblasts in the 
same upper chamber filled with low-serum medium (0.5% 
FBS), and the lower chamber was also filled with 0.5% 
FBS low-serum medium. After 24 h, migrating cells with 
GFP on the underside of inserts were imaged under a fluo-
rescent microscope (BZ-9000; Keyence, Tokyo, Japan). All 
the migrated GFP+ cells that migrated were counted by flu-
orescence-based scanning (Fluoroskan Ascent FL; Thermo 
Fisher Scientific).
Western Blot Analysis
Western blot analysis was performed under conventional 
conditions. The antibodies used were rabbit anti-COX2 
antibody (Cell Signaling Technology, Beverly, MA, USA), 
mouse anti-tubulin antibody (Sigma-Aldrich, St. Louis, 
MO, USA), and mouse anti-Myc antibody (Cell Signaling 
Technology). Agarose beads conjugated with monoclonal 
anti-HA tag antibody (Sigma-Aldrich) and monoclonal 
anti-Myc tag antibody (MBL, Nagoya, Japan) were used 
for coimmunoprecipitation experiments.
Mouse PDAC Model and its Evaluations
PK-8 cells (parental or PK-8 GFP clone, 2 × 106 cells 
or 3 × 106 cells) were subcutaneously transplanted into the 
back right side of BALB/c nu/nu mice (SLC, Hamamatsu, 
Japan) in either a single or mixed condition with the 
same number of normal human OUMS-24 fibroblasts 
(2 × 06 cells or 3 × 106 cells). The size of tumors was mea-
sured with a vernier caliper, and tumor volume was cal-
culated as 1/2 × (shortest diameter)2 × (longest diameter). 
After the tumor had grown at the injected site to 4–5 mm 
in diameter, either control IgG (100 µg/100 µl/mouse) or 
exRAGE-Fc (100 µg/100 µl/mouse) was subcutaneously 
administered into the back on the left side (nontumor 
area) of each mouse six times at constant 1-week inter-
vals (on days 3, 10, 17, 24, 31, and 38) for 44 days.
To count circulating tumor cells (CTCs) in the tumor-
bearing mice, 500 µl of whole blood was obtained from 
each mouse. The collected blood specimens were sup-
plemented with EDTA (final concentration 1 mg/ml), 
treated with 1.5 µl of red blood cell lysis buffer (Roche, 
Basel, Switzerland), and stained with APC-conjugated 
anti-CD45 antibody (BioLegend, San Diego, CA, USA), 
which is useful for distinguishing GFP-labeled cells 
(CTCs) from an abundant leukocyte population in the 
analytic image of flow cytometry. The treated speci-
mens were then subjected to flow cytometric analysis to 
count CTCs. Flow cytometry was performed on a MACS 
Quant Analyzer (Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany) using MACS Quantify Software 
Ver. 2.5 (Miltenyi Biotec GmbH). Data were analyzed 
using FlowJo software (FlowJo, LLC; BD Biosciences, 
Franklin Lakes, NJ, USA).
Statistical Analysis
Data are expressed as means ± SD. We employed sim-
ple pairwise comparison with Student’s t-test (two-tailed 
distribution with two-sample equal variance). A value of 
p < 0.05 was considered significant.
RESULTS AND DISCUSSION
We previously reported that S100A11 is markedly 
upregulated in PDAC cell lines at not only the intracel-
lular level but also the secreted extracellular level21. The 
active secretion of S100A11 from PDAC cell lines were 
also observed in clinical PDACs specimens since we 
found that S100A11 exhibits a tendency to increase in 
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serum from PDAC patients compared to that in serum 
from healthy donors (data not shown). Our recent work 
demonstrated that extracellular S100A11 secreted from 
PDAC cells significantly activates proliferation of adja-
cent fibroblasts but not PDAC cells via RAGE on the 
surface of fibroblasts, resulting in fertilization of PDAC 
stroma, which in turn enforces tumor progression in 
vivo21. In this experimental setting, we found that growth 
and motility of PDAC cells are pronouncedly upregulated 
by unidentified soluble factors secreted from S100A11-
stimulated fibroblasts. In this study, we therefore aimed 
to identify the soluble factor(s).
At first, in order to confirm the fibroblast role in 
tumor toward tumor progression in vivo, we transplanted 
PK-8 cells (a human PDAC cell line) alone or PK-8 cells 
mixed with human fibroblasts (OUMS-24 cells) into the 
subcutaneous area of nude mice. As shown in Figure 
1A and B, both tumor volume and weight were much 
larger in the group transplanted with mixed population 
of cells than in the group transplanted with only PK-8 
cells. To examine how S100A11 contributes to tumor 
progression with crosstalking between PDAC cells and 
fibroblasts, the behavior of PK-8 cells was examined 
under the presence of a condition medium (CM) from 
S100A11 (100 ng/ml)-stimulated OUMS-24 fibroblasts 
in a culture system [Supplementary Fig. 1A (growth) and 
B (migration), available at https://www.dropbox.com/
sh/58jtq8girxm80aw/AAA60uI3KPCPPkJ0x1JfG8O6
a?dl=0]. By this approach, we found that the CM from 
fibroblasts has the ability to greatly increase either prolif-
eration (Supplementary Fig. 1C) or migration (Fig. 1C) of 
PK-8 cells. Interestingly, although the upregulated growth 
of PK-8 cells with the nontreated fibroblast CM was not 
positively affected by the CM from S100A11-stimulated 
fibroblasts (Supplementary Fig. 1C), the increased ability 
of PK-8 cells for migration was further enhanced by the 
S100A11-treated fibroblast CM (Fig. 1C). In this experi-
mental setting, we confirmed that (1) S100A11 recombi-
nant protein alone set in the bottom chamber had no effect 
on PK-8 cell motility without fibroblasts (data not shown), 
(2) much higher doses (500 and 1,000 ng/ml) of S100A11 
did not result in further enhancement of migration activ-
ity in PK-8 cells through fibroblasts (Supplementary Fig. 
1D), and (3) S100A11 showed the highest activity for 
PK-8 cell migration in this coculture context among the 
cancer-relevant S100 proteins (S100A4, S100A8/A9, a 
heterodimer complex composed of S100A8 and S100A9, 
and S100A11) at 100 ng/ml (Supplementary Fig. 1E).
The increased motility with S100A11 was also seen 
in another PDAC cell line, PANC-1 (Fig. 1D). The 
exRAGE-Fc decoy that prevents S100A11 binding to 
intrinsic RAGE through capturing extracellular S100A1122 
reduced the enhanced migration of PK-8 cells by the 
S100A11-treated fibroblast CM (Fig. 1E), suggesting an 
important role of the S100A11–RAGE axis in fibroblasts 
for inducing a soluble factor(s) that activates PDAC cell 
motility. In this experimental setting, we also found that 
the basal migration ability of PK-8 cells caused by the 
nonstimulated fibroblast CM is reduced by treatment with 
exRAGE-Fc. This may be explained by the contribution 
of a RAGE ligand other than S100A11. Since S100A11 
is not secreted from fibroblasts21, we speculated that an 
unidentified RAGE ligand(s) secreted from fibroblasts 
cooperatively functions with S100A11 from PDAC cells 
to induce a certain PDAC chemoattractant(s) through 
RAGE on fibroblasts.
In a physiological condition, fibroblasts are attached 
to cancer cells in a PDAC tumor. We therefore cocultured 
PK-8 cells with WT mouse fibroblasts (WT fibroblasts) 
or RAGE KO mouse fibroblasts (RAGE−/− fibroblasts)21 
and examined the migration activity of PK-8 cells under 
the mixed condition (Supplementary Fig. 2A, available 
at https://www.dropbox.com/sh/58jtq8girxm80aw/AAA
60uI3KPCPPkJ0x1JfG8O6a?dl=0). To distinguish PK-8 
cells from fibroblasts in migration activity, we labeled 
PK-8 cells with green fluorescence protein (GFP) by a 
chromosomal insertion of the GFP gene expression unit 
that enables PK-8 cells to express GFP protein in a stable 
manner, resulting in creation of a control subline PK-8 
GFP clone (PK-8 GFP). At that time, to examine the 
effect of extracellular S100A11 on the mixed culture, we 
established an additional PK-8 subline (PK-8 GFP/A11) 
that stably expresses an abundant S100A11 other than 
GFP. We confirmed that the secretion level of S100A11 
in PK-8 GFP/A11 cells was about fivefold higher than 
that in PK-8 parental cells (Fig. 1F). Although PK-8 
GFP cells did not show migration and invasion activities 
in the absence of WT fibroblasts (data not shown), we 
found that migration and invasion were both induced in 
PK-8 GFP cells by cocultivation with WT fibroblasts and 
that these activities were further increased in PK-8 GFP/
A11 cells [Fig. 1G and Supplementary Figs. 2B (migra-
tion) and 1H (invasion)]. The upregulations were both 
in turn mitigated when the PK-8 sublines were mixed 
with RAGE−/− fibroblasts, suggesting a crucial role of the 
S100A11–RAGE axis in fibroblasts for activating inva-
sive motility of PDAC cells. In these experimental set-
tings, the increased activities of migration and invasion 
caused by S100A11 overexpression were not diminished 
to the basal migration level of control PK-8 GFP cells. 
This is probably due to the presence of another S100A11 
receptor(s) that is similar to RAGE in composition. We 
have reported RAGE-like receptors including melanoma 
cell adhesion molecule (MCAM), activated leukocyte 
cell adhesion molecule (ALCAM), extracellular matrix 
metalloproteinase inducer (EMMPRIN), and neuroplas-
tin (NPTN)26–28. These receptors react with other S100 
family proteins including S100A8/A9, a heterodimer 
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Figure 1. Effect of fibroblasts on pancreatic ductal adenocarcinoma (PDAC) progression through the S100A11–receptor for 
advanced glycation end products (RAGE) axis. (A) Tumor sizes were monitored on the indicated days after transplantation of the 
prepared cells [pancreatic carcinoma cells (PK-8 cells) alone (2 × 106 cells), PK-8 cells (2 × 106 cells) + normal human OUMS-24 
fibroblasts (2 × 106 cells)]. OUMS-24 fibroblasts showed no tumorigenesis when they were subcutaneously injected into nude mice 
as a single-cell population (data not shown). (B) Tumor weights were quantified 26 days after transplantation. (C–E) A migration 
assay was performed by the Boyden chamber method. PK-8 cells (C, E) and PANC-1 cells (D) were seeded on the top chambers to 
be 5 × 104 cells/chamber. OUMS-24 fibroblasts (5 × 104 cells) were set on each bottom chamber to constantly supply the fibroblast-
conditioned medium. OUMS-24 fibroblasts in the bottom chamber were then stimulated (+) or not stimulated (−) with S100A11 
at a final concentration of 100 ng/ml (C–E). (E) To prevent S100A11–RAGE interaction on OUMS-24 fibroblasts, exRAGE-Fc 
(1.0 µg/ml) was also added to the same bottom chamber. Cancer cell migration was assessed at 24 h after setting of the assay 
(C–E). (F) The secretion level of S100A11 from a PK-8 GFP/A11 stable clone was evaluated by monitoring S100A11 in its cul-
tured medium with ELISA in comparison to that from parental PK-8 cells. (G, H) A GFP-labeled PK-8 clone (PK-8 GFP or PK-8 
GFP/A11) (5 × 104 cells) was mixed with mouse WT fibroblasts or mouse RAGE−/− fibroblasts and placed on the top chamber (see 
Supplementary Fig. 2A). Twenty-four hours after cultivation, the PK-8 cells that had migrated (G) or invaded (H) were monitored 
by the expressed GFP color. The graphs show quantified data of migration (G) and invasion (H) events. Data are means ± SD; N.S., 
not significant; *p < 0.05 and **p < 0.01.
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complex composed of S100A8 and S100A9. Our RNA-
seq data demonstrated that MCAM alone was elevated 
among the receptors at a significant level when RAGE 
was knocked out in mouse fibroblasts21. We hence con-
sidered that MCAM may function as a compensatory 
receptor to S100A11 in fibroblasts to maintain cellu-
lar homeostasis, and this issue about the interaction of 
S100A11 with MCAM and its physiological role in the 
cancer microenvironment is part of our ongoing study.
In order to obtain a mechanistic clue regarding the 
positive regulation of cancer motility by activated 
fibroblasts through the S100A11–RAGE axis, we per-
formed comparative analysis of gene expression, with 
focus on genes encoding soluble secretory proteins, in 
Figure 2. Significant role of prostaglandin E2 (PGE2) in upregulation of PDAC cell migration induced by the S100A11–RAGE axis 
in fibroblasts. (A) PGE2 levels in sera collected from PDAC patients were monitored and quantified by ELISA. (B, C) In vitro migra-
tion of PK-8 cells was evaluated by a method similar to that described in the legend of Figure 1E except for the use of cyclooxygenase 
(COX) inhibitors, aspirin (inhibitor of COX1 and COX2, B) and meloxicam (selective inhibitor of COX2, C) in the bottom chamber 
in which fibroblasts were present. (D) Cellular invasion of PK-8 cells was also evaluated by a method similar to that described above 
(C) except for the use of Matrigel-covered membrane set in the Transwell chamber. (E) Culture media of OUMS-24 fibroblasts were 
collected after treatment of the cells with S100A11 (100 ng/ml, 24 h) in the presence or absence of a tumor progression locus 2 (TPL2) 
inhibitor or meloxicam. The culture media were then subjected to ELISA to monitor the PGE2 levels in the media. (F, G) Migration 
(F) and invasion (G) assays were performed using a Boyden chamber. PK-8 cells (5 × 104 cells) were set in the top chamber, and PGE2 
was added to the bottom chamber without fibroblasts. PK-8 cell migration was assessed at 24 h after addition of PGE2 to 10% FBS 
medium set in the bottom chamber. Data are means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.
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mouse WT fibroblasts treated with and not treated with 
S100A11. However, unexpectedly, the results of RNA-
seq analysis showed that there were no appreciable dif-
ferences in gene expression (data not shown). We then 
examined the alteration of gene expression in mouse WT 
fibroblasts compared to that in mouse RAGE−/− fibro-
blasts and found that several cancer-related soluble fac-
tors were downregulated in mouse RAGE−/− fibroblasts 
(Supplementary Fig. 3A, available at https://www.dropbox.
com/sh/58jtq8girxm80aw/AAA60uI3KPCPPkJ0x1JfG8O6
a?dl=0). Among the altered genes, we selected genes that 
are highly relevant to cancer progression (highlighted by 
red color)29–34. Their downregulation that happened in 
concomitant to RAGE KO was confirmed by the quanti-
tative real-time PCR technique (Supplementary Fig. 3B). 
However, the expression levels of the altered genes of 
interest were not enhanced by treatment with S100A11 
in mouse WT fibroblasts (Supplementary Fig. 4A, avail-
able at https://www.dropbox.com/sh/58jtq8girxm80aw/
AAA60uI3KPCPPkJ0x1JfG8O6a?dl=0) or in human 
OUMS-24 fibroblasts except for a subtle increase in matrix 
metalloproteinase MMP13 (Supplementary Fig. 4B). 
These negative results spurred us next to focus on another 
candidate, fatty acids, which act as powerful cancer 
chemoattractants. It has long been recognized that prosta-
glandin E2 (PGE2) plays an unusual role in cancer growth 
and metastasis,35 and PGE2 was actually upregulated in 
serum from PDAC patients (Fig. 2A). We hence tried to 
examine the role of PGE2 in PDAC by suppressing the 
production of PGE2 in fibroblasts using cyclooxygenase 
(COX) inhibitors (aspirin: inhibitor of COX1 and COX2, 
meloxicam and etodolac: selective inhibitor of COX2). 
As shown in Figure 2B and C and Supplementary Figures 
5 (migration) and 2D (invasion) (available at https://www.
dropbox.com/sh/58jtq8girxm80aw/AAA60uI3KPCPPk
J0x1JfG8O6a?dl=0), these inhibitors effectively elimi-
nated the activation force of S100A11-stimulated fibro-
blasts, resulting in the reduction of both migration and 
invasion of PK-8 cells in a dose-dependent manner with-
out apoptotic cell death in the treated fibroblasts. In par-
allel with this, we confirmed that meloxicam effectively 
suppressed PGE2 production in human OUMS-24 fibro-
blasts (Fig. 2E). In addition, we found that extracellular 
PGE2 at 25 nM is sufficient to stimulate the migration of 
PK-8 cells, and the treatment at 50 nM shows the highest 
induction of the migration (Fig. 2F). We also confirmed 
that 50 nM of PGE2 is enough to activate an invasive 
movement of PK-8 cells (Fig. 2G). One reason for cel-
lular migration requiring higher concentration (25 nM) 
than the physiological concentration induced by S100A11 
is probably deterioration of the stocked PGE2 reagent 
since unsaturated fatty acids are rapidly inactivated by 
oxidization. Endogenous fresh PGE2 may have higher 
activity than that of the stocked one. Collectively, the 
results suggest an important role of fibroblast-mediated 
secretory PGE2 in positive regulation of PDAC cell 
motility, which is triggered by the S100A11–RAGE–
COX2 axis in fibroblasts.
Our next interest was how PGE2 is induced by RAGE 
upon S100A11 binding. To examine a RAGE down-
stream signal that is required for COX2 activation and 
subsequent production of PGE2, we attempted to identify 
a signal upstream kinase as a novel binding partner to 
RAGE that may trigger the signal onset of RAGE in the 
cytoplasm. Each of the mitogen-activated protein kinase 
kinase kinases (MAPKKKs: NAK, NIK, TAK1, DLK, 
TPL2, ASK1, SPRK, MLK1, MEKK3, LZK, and MLK4) 
and MAPKK (MKK5) was cotransfected with RAGE in 
HEK293T cells, and their interactions were studied by 
an immunoprecipitation (IP) technique. By this approach, 
we found novel interactions of RAGE with TPL2 and 
ASK1 (Fig. 3A). Given that these interactions are impor-
tant to induce PGE2 production, we asked the significance 
of the recruitment of the kinases to RAGE in activation of 
COX2 in fibroblasts. Interestingly, functional inhibition of 
TPL2, but not that of ASK1, reduced either the S100A11-
mediated induction of COX2 (Fig. 3B) or PGE2 (Fig. 2E) in 
OUMS-24 fibroblasts at a pronounced level. Both a TPL2 
inhibitor (Fig. 3C) and overexpression of a kinase-dead 
type of TPL2 (TPL2-KD) (Supplementary Fig. 6, avail-
able at https://www.dropbox.com/sh/58jtq8girxm80aw/
AAA60uI3KPCPPkJ0x1JfG8O6a?dl=0) also markedly 
attenuated the ability of fibroblasts to induce upregu-
lation of PK-8 cell motility with the help of S100A11. 
These results indicate a crucial role of the S100A11–
RAGE–COX2–PGE2 axis in fibroblasts for PDAC pro-
gression with increased motility of adjacent cancer cells. 
A linkage between TPL2 and COX2 was also reported in 
macrophages in response to a lipopolysaccharide (LPS)35. 
In that study, it was revealed that regulation of COX2 by 
TPL2 depends on the ERK-MAPK (ERK) and p38-MAPK 
(p38) pathways, which activate CREB, a critical enhancer 
of COX2 transcription. A similar mechanism may function 
in the RAGE downstream in fibroblasts upon S100A11 
binding since we also detected increased phosphorylation 
of ERK2, but not that of ERK1, or p38 for all of its iso-
forms (p38a, b, d, and g) (Supplementary Fig. 7, available 
at https://www.dropbox.com/sh/58jtq8girxm80aw/AAA6
0uI3KPCPPkJ0x1JfG8O6a?dl=0).
Last, we extended our research to an animal model 
for PDAC progression with increased cell motility of 
cancer cells. In order to confirm the important role of 
RAGE in cancer-associated fibroblasts for tumor growth 
and cancer cell motility, we subcutaneously transplanted 
a mixture of PK-8 cells and OUMS-24 fibroblasts and 
evaluated their growth (Fig. 4A and B) and cancer cell 
motility (Fig. 4C) after injection of either control IgG 
or exRAGE-Fc. In this experimental setting, cancer cell 
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Figure 3. Significant role of TPL2 in induction of COX2 through S100A11–RAGE interaction in fibroblasts, which greatly contrib-
utes to the upregulation of PDAC cell migration caused by S100A11-stimulated fibroblasts. (A) HEK293T cells were cotransfected 
with HA-tagged RAGE and each of the indicated Myc-tagged upstream kinases, NAK (NF-kB-activating kinase: TBK1), NIK (NF- 
kB-inducing kinase: MAP3K14), TAK1 (TGF-b activated kinase 1: MAP3K7), DLK (dual leucine zipper-bearing kinase: MAP3K12), 
TPL2 (MAP3K8), ASK1 (apoptosis signal-regulating kinase 1: MAP3K5), SPRK (Src-homology 3 domain-containing proline-rich 
kinase: MAP3K11), MLK1 (mixed lineage kinase 1: MAP3K9), MEKK3 (MAPK/ERK kinase kinase 3: MAP3K3), LZK (leucine 
zipper-bearing kinase: MAP3K13), MLK4 (mixed lineage kinase 4: MAP3K21), and MKK5 (MAP kinase kinase 5: MAP2K5). After 
immunoprecipitation of the expressed RAGE with HA antibody-conjugated beads, kinases that interacted were detected by Myc 
antibody. Circles painted black show the candidates that interacted with RAGE. (B) COX2 induction was monitored in OUMS-24 
fibroblasts by Western blotting. OUMS-24 fibroblasts were treated or not treated with S100A11 (100 ng/ml, 24 h) in the presence or 
absence of the indicated inhibitors (ASK1 inhibitor and TPL2 inhibitor). (C) A migration assay was performed by a method similar to 
that described in the legend of Figure 2B–D except for the use of different inhibitors (ASK1 inhibitor and TPL2 inhibitor). Data are 
means ± SD. N.S., not significant; *p < 0.05.
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motility was assessed by monitoring the number of cir-
culating tumor cells (CTCs) since we confirmed that 
PK-8 cells never showed aggressive metastatic behavior 
to distant organs such as the lung, liver, and brain from 
the subcutaneous primary tumor area even when mixed 
with fibroblasts (data not shown). However, given that 
migration activity of PK-8 cells is highly elevated at 
the primary tumor area by fibroblasts, some cells will 
actively disseminate and enter the blood stream as CTCs. 
As a result, we found that tumor volume (Fig. 4A), 
tumor weight (Fig. 4B), and number of CTCs (Fig. 4C) 
were all markedly elevated in the group with a mixed 
tumor (PK-8 GFP cells and OUMS-24 fibroblasts) com-
pared to those in the group with a tumor derived from 
only PK-8 GFP cells. Treatment of the mixed tumor 
with exRAGE-Fc tended to suppress tumor growth and 
decrease the number of CTCs. These results suggest that 
RAGE in fibroblasts contributes to an increase in the 
number of CTCs as well as tumor growth in an in vivo 
situation (Fig. 4D).
Here we could not yet be sure at the time that although 
PDAC patients have increased PGE2 levels in their sera 
compared with those in healthy donors as shown in Figure 
2A, S100A11–RAGE–TPL2–COX2 axis in fibroblasts 
Figure 4. Effect of exRAGE-Fc on PDAC progression in vivo. (A) Tumor sizes were monitored on the indicated days after transplan-
tation of the prepared cells [PK-8 GFP cells alone (3 × 106 cells), PK-8 GFP cells (3 × 106 cells) + OUMS-24 fibroblasts (3 × 106 cells)]. 
Mice that were injected with the mixed cells (PK-8 GFP/OUMS-24) were treated with either control IgG (100 µg/100 µl/mouse) or 
exRAGE-Fc (100 µg/100 µl/mouse) six times at constant 1-week intervals (on days 3, 10, 17, 24, 31, and 38) for 44 days. Data are 
means ± SD. *p < 0.05, **p < 0.01 (PK-8 GFP + OUMS-24 + exRAGE-Fc vs. PK-8 GFP + OUMS-24 + IgG) or †p < 0.05 and ††p < 0.01 
(PK-8 GFP + OUMS-24 + exRAGE-Fc vs. PK-8 GFP). (B) Tumor weights were quantified 44 days after transplantation. Data are 
means ± SD. *p < 0.05. (C) After 44 days of the tumor monitoring, PK-8 GFP clone-derived circulating tumor cells (CTCs) from the 
indicated three groups were evaluated by flow cytometry using collected mouse whole blood specimens (500 µl/mouse). The gated 
GFP+ cell populations are quantified, and the resulting data that express cell numbers are shown by bar graphs. Data are means ± SD. 
*p < 0.05. (D) The schematic shows a reaction model of the identified pathway that plays a crucial role in PDAC progression through
crosstalking between PDAC cells and adjacent fibroblasts, leading to an increased level of CTCs, which may greatly contribute to the 
increase in metastatic aggressiveness of PDAC.
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actually functions to upregulate PGE2 in the patient’s 
 living body. In this issue, Xie et al. reported the rise in the 
concentration of PGE2 in PDAC-bearing mice, in which 
tumor-induced elevation of PGE2 (around 70 pg/mg) was 
reduced to around 30 pg/mg by a COX2 inhibitor36. It also 
followed that COX2 inhibitor efficiently blocked tumor 
progression in the mouse xenograft model of PDAC. This 
implies an important role of COX2-mediated PGE2 pro-
duction in PDAC progression in vivo. We hence support 
the idea that our identified S100A11–RAGE–TPL2 axis 
contributes in part to the activation of COX2, which in 
turn induces PGE2 in vivo.
As already explained, a RAGE ligand is not restricted 
to S100A11. Various ligands are present in an in vivo 
environment (living body) rather than in an in vitro envi-
ronment (cell culture system). We hence considered the 
possibility that several other ligands in a living body 
other than PK-8 cell-derived S100A11 bind to RAGE on 
cancer neighboring fibroblasts, resulting in production 
of several soluble proteins (Supplementary Fig. 3B) that 
may greatly contribute to cancer growth with a mutual 
cooperation among them. On the other hand, we revealed 
that S100A11 from PDAC cells induces the production 
of soluble fatty acid PGE2 in cancer-associated fibro-
blasts through activation of the RAGE–TPL2–COX2 
pathway, which in turn can activate PDAC motil-
ity, eventually leading to an increase in the number of 
CTCs in in vivo situation. In this experimental setting, 
exRAGE-Fc resulted in showing a tendency to suppress 
tumor growth (Fig. 4B) as well as showing a tendency 
to reduce the number of CTCs (Fig. 4C), but both sup-
pressive effects were not significant. These results may 
be explained by the presence of receptors similar to 
RAGE such as MCAM in fibroblasts since MCAM 
may be upregulated by suppression of RAGE as cellular 
compensatory machinery even in an in vivo situation21. 
Further studies are required to elucidate these elaborate 
mechanisms.
CONCLUSION
In this study, we revealed an unusual role of fibro-
blasts in upregulation of PDAC cell motility that requires 
certain crosstalking between PDAC cells and surround-
ing fibroblasts in the cancer stroma through PDAC cell-
secreted S100A11 and its receptor RAGE on fibroblasts. 
In this context, we found that PGE2, which is induced by 
the S100A11–RAGE–TPL2–COX2 axis in fibroblasts, 
functions as a key soluble factor to accelerate PDAC 
cell motility, resulting in an increased number of CTCs 
in vivo. In addition, we found that RAGE in fibroblasts 
also contributes to the upregulation of PDAC growth in 
vivo. Thus, the establishment of a strategy for targeting 
the S100A11–RAGE–TPL2–COX2 pathway in CAFs 
in PDAC may provide an advanced benefit for a thera-
peutic approach for PDACs that are difficult to treat. In 
fact, exRAGE-Fc showed a tendency to suppress PDAC 
growth and reduce the concomitant increase in the num-
ber of CTCs in vivo.
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